These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 26267731)

  • 1. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R; Unnebrink K; Valdecantos WC
    J Drugs Dermatol; 2015 Aug; 14(8):864-8. PubMed ID: 26267731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
    Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
    Papp KA; Armstrong AW; Reich K; Karunaratne M; Valdecantos W
    Am J Clin Dermatol; 2016 Feb; 17(1):79-86. PubMed ID: 26547918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis.
    Navarini AA; Poulin Y; Menter A; Gu Y; Teixeira HD
    J Drugs Dermatol; 2014 May; 13(5):554-62. PubMed ID: 24809878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
    Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
    Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
    Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
    J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
    J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study.
    Saurat JH; Langley RG; Reich K; Unnebrink K; Sasso EH; Kampman W
    Br J Dermatol; 2011 Aug; 165(2):399-406. PubMed ID: 21564071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
    Salim A; Tan E; Ilchyshyn A; Berth-Jones J
    Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.
    Armstrong AW; Villanueva Quintero DG; Echeverría CM; Gu Y; Karunaratne M; Reyes Servín O
    Am J Clin Dermatol; 2016 Dec; 17(6):691-699. PubMed ID: 27815915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
    Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.